Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: C09CA09

Edarbi(azilsartan medoxomil)

Hypertension

Marketing Authorisation Holder: Takeda Pharma A/S

EMA Authorisation: 07/12/2011

INN: azilsartan medoxomil

Indication

Edarbi is indicated for the treatment of essential hypertension in adults.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Edarbi — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.